· Regulation · Regulation Desk
The FDA will convene a summer Pharmacy Compounding Advisory Committee to weigh BPC-157 and six other peptides for the 503A bulks list. We break down what a 'yes' vote would — and wouldn't — change for compounded peptide access.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.